Granulocyte-macrophage colony-stimulating factor (GM-CSF) ameliorates chemotherapy-induced neutropenia in children with solid tumorsvan Pelt, L. J., de Craen, A. J., Langeveld, N. E. & Weening, R. S., 31-Dec-1997, In : Pediatric hematology and oncology. 14, 6, p. 539-45 7 p.
Research output: Contribution to journal › Article › Academic › peer-review
Neutropenia is one of the risk factors for severe therapy-related morbidity in childhood malignancies. We have studied the potential of GM-CSF to shorten the neutropenic period after normal-dose chemotherapy in children who were treated for solid tumors. Patients with osteosarcomas, with Ewing sarcomas, or with rhabdomyosarcomas received 10 daily subcutaneous doses GM-CSF (Leucomax, 5 micrograms/kg) after a course of normal-dose chemotherapy in an open-label study. Because these patients were treated with different combinations of chemotherapeutic agents, they were randomized before each pair of identical courses of chemotherapy to receive GM-CSF after the first or after the second course. Fourteen such combinations could be evaluated in eight patients. The results show that GM-CSF significantly reduced the mean duration of the chemotherapy-induced neutropenia (mean reduction +/- SEM in days: 2.2 +/- 0.6, P = .003). There was no significant difference between the mean number of days with fever in either group. GM-CSF was well tolerated by all patients. We conclude that GM-CSF reduced the mean neutropenic period in children with solid tumors who were treated with standard-dose chemotherapy.
|Number of pages||7|
|Journal||Pediatric hematology and oncology|
|Publication status||Published - 31-Dec-1997|
- Adolescent, Antineoplastic Agents/adverse effects, Child, Child, Preschool, Female, Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use, Humans, Infant, Male, Neoplasms/drug therapy, Neutropenia/drug therapy, Osteosarcoma/drug therapy, Rhabdomyosarcoma/drug therapy, Sarcoma, Ewing/drug therapy